Back to Questions
Question ID: WS-62
Submitted by: Ignacio Melero
February 12, 2011
Comments
Question ID: WS-62
Submitted by: Ignacio Melero
February 12, 2011
How can we translate preclinical success with combinatorial immunotherapies to patients? Background: Compelling preclinical evidence speaks of synegisitic combination treatments involving various immunostimulatory monoclonal antibodies (CD40, CTLA-4, PD-1, CD137, OX40), adoptive T cell transfer and cancer vacines. Examples of synergistic therapeutic effects are also observed between novel immunotherapies and conventional treatment modalities including chemotherapy. There are Problems (in part real and in part perceived) for development. These include complex and largely undefined regulatory requirements for the combinations, entangled business and intelectual property issues, and very expensive logistics for the trials.
| This question has not yet been evaluated by users |
Comments
